NEW YORK (GenomeWeb) – ImaBiotech and iTeos Therapeutics today announced that they have received a two-year €800,000 grant ($867,544) from the Walloon Region of Belgium and Bpifrance to fund research characterizing the microenvironment of tumor tissues.

Belgian therapeutics firm iTeos will contribute immune-oncology animal models and tissue libraries for metabolite profiling using ImaBiotech's Multimaging combined mass spectrometry imaging and immunohistology technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.